These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 31465296)

  • 21. Changes in Body Mass Index in Girls with Idiopathic Central Precocious Puberty under Gonadotropin-Releasing Hormone Analogue Therapy: The Spanish Registry.
    Corripio R; Soriano-Guillén L; Herrero FJ; Cañete R; Castro-Feijoó L; Escribano A; Espino R; Labarta JI; Argente J
    Horm Res Paediatr; 2016; 86(3):154-160. PubMed ID: 27529349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduction of baseline body mass index under gonadotropin-suppressive therapy in girls with idiopathic precocious puberty.
    Arrigo T; De Luca F; Antoniazzi F; Galluzzi F; Segni M; Rosano M; Messina MF; Lombardo F
    Eur J Endocrinol; 2004 Apr; 150(4):533-7. PubMed ID: 15080784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gonadotropin releasing hormone analogue therapy in girls with idiopathic precocious puberty/early-fast puberty: dynamics in adiposity indices, eating habits and quality of life.
    Loochi SA; Demol S; Nagelberg N; Lebenthal Y; Phillip M; Yackobovitch-Gavan M
    J Pediatr Endocrinol Metab; 2021 Mar; 34(3):373-383. PubMed ID: 33609438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of GnRH analog treatment on BMI in children treated for precocious puberty: a systematic review and meta-analysis.
    Zhu X; Qin J; Xue W; Li S; Zhao M; Yingliang Jin
    J Pediatr Endocrinol Metab; 2024 Apr; 37(4):297-308. PubMed ID: 38407229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty.
    Lee PA; Klein K; Mauras N; Lev-Vaisler T; Bacher P
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3153-9. PubMed ID: 24926950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The alteration of IGF-1 levels and relationship between IGF-1 levels and growth velocity during GnRH analogue therapy.
    Muratoglu Sahin N; Peltek Kendirci HN; Çetinkaya S; Savaş Erdeve Ş; Aycan Z
    J Pediatr Endocrinol Metab; 2020 Jan; 33(1):113-120. PubMed ID: 31809263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty.
    Boot AM; De Muinck Keizer-Schrama S; Pols HA; Krenning EP; Drop SL
    J Clin Endocrinol Metab; 1998 Feb; 83(2):370-3. PubMed ID: 9467543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gonadotropin-releasing hormone analogs treatment in girls with central precocious puberty and early fast puberty.
    Lerman L; Yackobovitch-Gavan M; Phillip M; Shalitin S
    Pediatr Res; 2024 Mar; 95(4):1051-1059. PubMed ID: 37935883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum levels of growth hormone binding protein in children with normal and precocious puberty: relation to age, gender, body composition and gonadal steroids.
    Juul A; Fisker S; Scheike T; Hertel T; Müller J; Orskov H; Skakkebaek NE
    Clin Endocrinol (Oxf); 2000 Feb; 52(2):165-72. PubMed ID: 10671943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the resilience of the girls with central precocious puberty treated with gonadotropin-releasing hormone analog.
    Odabasi Gunes S; Akin O; Eray S
    J Pediatr Endocrinol Metab; 2021 Nov; 34(11):1379-1384. PubMed ID: 34313086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Weight evolution in girls treated for idiopathic central precocious puberty with GnRH analogues.
    Aguiar AL; Couto-Silva AC; Vicente EJ; Freitas IC; Cruz T; Adan L
    J Pediatr Endocrinol Metab; 2006 Nov; 19(11):1327-34. PubMed ID: 17220061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.
    Boepple PA; Mansfield MJ; Wierman ME; Rudlin CR; Bode HH; Crigler JF; Crawford JD; Crowley WF
    Endocr Rev; 1986 Feb; 7(1):24-33. PubMed ID: 2937629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Impact of gonadotropin-releasing hormone analogs on body mass index in girls with idiopathic central precocious puberty: a long-term follow-up study].
    Yuan JN; Liang L; Cai XD; Li Z; Bai M; Gu CP
    Zhongguo Dang Dai Er Ke Za Zhi; 2011 Nov; 13(11):896-9. PubMed ID: 22099200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Body mass index and body composition in adolescents treated with gonadotropin-releasing hormone analogue triptorelin depot for central precocious puberty: data at near final height.
    Chiocca E; Dati E; Baroncelli GI; Mora S; Parrini D; Erba P; Bertelloni S
    Neuroendocrinology; 2009; 89(4):441-7. PubMed ID: 19176945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of gonadotropin releasing hormone analogue therapy on girls with gonadotropin-dependent precocious puberty.
    Tung YC; Lee JS; Tsai WY; Hsiao PH
    J Formos Med Assoc; 2007 Oct; 106(10):826-31. PubMed ID: 17964961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elevated Random Luteinizing Hormone is an Unreliable Indicator for Pubertal Suppression in Girls Treated with Monthly Leuprolide for Idiopathic Central Precocious Puberty.
    Wiromrat P; Panamonta O
    J Clin Res Pediatr Endocrinol; 2019 Sep; 11(3):227-233. PubMed ID: 30592192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased final adult height by gonadotropin-releasing hormone agonist in girls with idiopathic central precocious puberty.
    Lee HS; Yoon JS; Park KJ; Hwang JS
    PLoS One; 2018; 13(8):e0201906. PubMed ID: 30133462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of gonadotropin-releasing hormone analog treatment (leuprolide) on body fat distribution in idiopathic central precocious puberty.
    Taşcilar ME; Bilir P; Akinci A; Köse K; Akçora D; Inceoğlu D; Fitöz SO
    Turk J Pediatr; 2011; 53(1):27-33. PubMed ID: 21534336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Girls with idiopathic central precocious puberty did not display substatial changes in body mass index after treatment with gonadotropin-releasing hormone analogues.
    Uldbjerg CS; Lim YH; Renault CH; Hansen D; Juul A; Bräuner EV; Jensen RB
    Acta Paediatr; 2024 Jul; 113(7):1602-1611. PubMed ID: 38506052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Occurrence of slipped capital femoral epiphysis in children undergoing gonadotropin-releasing hormone agonist therapy for the treatment of central precocious puberty.
    Inman M; Hursh BE; Mokashi A; Pinto T; Metzger DL; Cummings EA
    Horm Res Paediatr; 2013; 80(1):64-8. PubMed ID: 23859950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.